

Meningococcal C Conjugate (MCC) Vaccine

NEISVAC-C®

Supplier: Pfizer Canada Inc. ^A

MENJUGATE®

Supplier: Novartis Pharmaceuticals Canada Inc.

INDICATIONS:

- Primary infant series (NeisVac-C® to be used)
- Children who have not received a dose of MCC vaccine after 12 months of age, and who are younger than Grade 9
- Adolescents and adults born prior to January 1, 2002, who have not received a dose of MCC vaccine at 10 years of age or older ^B
- Close contacts (2 months of age and older) of a case of invasive meningococcal group C disease who meet the public health criteria for immunoprophylaxis ^C
- Medically high risk individuals see [Part 2 – Immunization of Special Populations](#)

DOSES AND SCHEDULE:

Primary infant series: 2 doses given as 0.5 mL **IM** at 2 and 12 months of age, at least 8 weeks apart.

Eligible children 12 months of age and older: 1 dose given as 0.5 mL **IM**, at least 8 weeks after prior dose.

Eligible adolescents and adults: 1 dose given as 0.5 mL **IM**.

Close contacts of a case of invasive meningococcal group C disease: ^C

2-11 months of age: 3 doses given as 0.5 mL **IM** with at least 8 weeks between doses. The 3rd dose should be administered at 12 months of age or older.

12 months of age and older: 1 dose given as 0.5 mL **IM**.

Medically high risk: See [Part 2 – Immunization of Special Populations](#).

ADMINISTRATION:

MENJUGATE®:

This product needs to be reconstituted.

NEISVAC-C®:

No additional requirements.

BOOSTER DOSES:

No booster doses are recommended at this time.

^A NeisVac-C® is transitioning from GlaxoSmithKline Inc. to Pfizer Canada Inc. in 2016. During the transition period, both GSK and Pfizer labelled products may be in use.

^B These individuals are eligible up to 24 years of age (inclusive).

^C If client is a close contact meeting public health criteria for immunoprophylaxis, this dose should be given as soon as serotype information is available. For immunization of close contacts who have received prior meningococcal conjugate vaccine doses see [Communicable Disease Control Manual Chapter 1: Meningococcal Disease](#). Vaccine may be administered concurrently with chemoprophylaxis.

Meningococcal C Conjugate (MCC) Vaccine

NEISVAC-C®

Supplier: Pfizer Canada Inc.

MENJUGATE®

Supplier: Novartis Pharmaceuticals Canada Inc.

SEROLOGICAL TESTING:

Serological testing is not recommended before or after immunization.

CONTRAINDICATIONS:

1. History of anaphylactic reaction to a previous dose of any meningococcal vaccine or to any component of the specific vaccine to be given (i.e., NEISVAC-C® or MENJUGATE®) or to latex (in MENJUGATE® only).

PRODUCT COMPONENTS:

NEISVAC-C®:

Potential allergens: tetanus toxoid protein.

Other components: aluminum hydroxide.

MENJUGATE®:

Potential allergens: diphtheria CRM₁₉₇ toxoid protein, latex.

Other components: aluminum hydroxide, sodium dihydrogen phosphate monohydrate, disodium phosphate heptahydrate, mannitol.

PRECAUTIONS:

Not applicable.

SPECIAL CONSIDERATIONS:

- NEISVAC-C® is the recommended and supplied product for the primary infant series. Any meningococcal C conjugate vaccine may be used for doses given at 18 months of age or older.
- There must be an interval of at least 6 months between the administration of a meningococcal polysaccharide vaccine and a meningococcal C conjugate vaccine.

ADVERSE EVENTS:

Local: pain, redness, swelling.

Systemic: crying, irritability, change in appetite, drowsiness, somnolence or impaired sleeping, diarrhea, vomiting, nausea, headache, fever, malaise, myalgia.